No Data
No Data
Zhejiang Conba Pharmaceutical (600572.SH): ZY13 extract and tablets have obtained the drug clinical trial approval letter.
On October 21st, Kangenbei (600572.SH) announced that the company has received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration for the ZY13 extract and tablets. The ZY13 tablets for clinical trials applied by the company are indicated for age-related macular degeneration caused by kidney yin deficiency and hyperactivity of fire, administered orally, and classified as a new traditional chinese medicine category 1.2 drug. The most appropriate dosage will be confirmed after the clinical trial ends. The pharmacological experiments conducted on this product have shown that the ZY13 extract has the effect of inhibiting choroidal neovascularization. As of now, the company has invested in this product.
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Market Cap Dropped CN¥930m Last Week; Individual Investors Bore the Brunt
Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) A Risky Investment?
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Zhejiang Conba Pharmaceutical 2024 Interim Report Summary
Zhejiang Conba Pharmaceutical 2024 Interim Report Full Text
No Data
No Data